{
  "drug_name": "Clozapine",
  "url": "https://wikem.org/wiki/Clozapine",
  "scraped_at": "2026-01-10T07:50:43.909697",
  "sections": {
    "General": {
      "text": "Type: Atypical\nantipsychotic\nDosage Forms:\n12.5, 25, 50, 100, 200\n12.5, 25, 50, 100, 150, 200 ODT\nCommon Trade Names: Clozaril, FezaClo, Versacloz",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "antipsychotic",
          "url": "https://wikem.org/wiki/Antipsychotic"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Schizophrenia,_resistant": {
          "text": "150-300mg PO BID\nstart: 12.5mg PO QD-bid, increase by 25-50mg/day to target 300-450mg/day in divided doses by day 14; then may increase by up to 100mg/day q3-7days;\nmax 900mg/day\nretitrate from 12.5mg PO QD-bid if treatment interrupted > 2 d\ntaper dose over 1-2 weeks to DC",
          "tables": []
        },
        "Suicide_prevention,_schizophrenia-associated": {
          "text": "150-300mg PO BID\nstart, increase, retitrate, and DC as above",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Schizophrenia,_resistant": {
      "text": "150-300mg PO BID\nstart: 12.5mg PO QD-bid, increase by 25-50mg/day to target 300-450mg/day in divided doses by day 14; then may increase by up to 100mg/day q3-7days;\nmax 900mg/day\nretitrate from 12.5mg PO QD-bid if treatment interrupted > 2 d\ntaper dose over 1-2 weeks to DC",
      "subsections": {
        "Suicide_prevention,_schizophrenia-associated": {
          "text": "150-300mg PO BID\nstart, increase, retitrate, and DC as above",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Suicide_prevention,_schizophrenia-associated": {
      "text": "150-300mg PO BID\nstart, increase, retitrate, and DC as above",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "Schizophrenia (limited data - adjusted dose based on tolerability, clinical response)\nChildren >6 years PO 6.25 or 12.5mg qd\nAdolescents 12.5mg 1-2x daily",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: B (no evidence of risk)\nLactation: possibly unsafe\nRenal Dosing\nAdult\nnot defined, consider decreasing dose for significant impairment\nPediatric\nnot available\nHepatic Dosing\nAdult\nnot defined, consider decreasing dose for significant impairment\nPediatric\nnot available",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        }
      ]
    },
    "Indications": {
      "text": "Controls positive and negative symptoms of psychotic disorders\nUsed for schizophrenia\nOff label use:\nBipolar disorder\nBorderline personality disorder",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nhistory of clozapine-associated myocarditis\nhistory of agranulocytosis or granulocytopenia\nuncorrected electrolyte abnormalities\ncaution in elderly, stroke, dementia, CAD, prolonged QT\ncaution if history of torsades de pointes, ventricular arrhythmias\ncaution if bradycardic, recent MI, CHF\ncaution if eosinophila\ncaution if pulmonary disease, hepatic impairment, seizure risk\ncaution if BPH, angle-closure glaucoma, DM\ncaution if PKU",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "QT prolongation\nMyocarditis\nAgranulocytosis\nin 1%–2% of patients during initial treatment 3 months\nHighest ~3 months into treatment and then decreases\nOther potential side effects:\nDyslipidemia\nDiabetes\nDecreased seizure threshold\n\"Other adverse cardiovascular and respiratory effects\"\n[1]\n\"Increased mortality in elderly patients with dementia-related psychosis\"\n[1]",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "QT prolongation",
          "url": "https://wikem.org/wiki/QT_prolongation"
        },
        {
          "text": "Myocarditis",
          "url": "https://wikem.org/wiki/Myocarditis"
        },
        {
          "text": "Agranulocytosis",
          "url": "https://wikem.org/wiki/Agranulocytosis"
        }
      ]
    },
    "Pharmacology": {
      "text": "Half-life:  4-66h\nMetabolism:  liver extensively\nExcretion: urine 50%, feces 30%\nMechanism of Action: exact mechanism of action unknown, antagonizes dopamine D2, serotonin 5-HT2, α adrenergic, cholinergic muscarinic receptors, others",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Schizophrenia\nBipolar disorder\nBorderline personality disorder\nAntipsychotics\nAntipsychotic toxicity",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Schizophrenia",
          "url": "https://wikem.org/wiki/Schizophrenia"
        },
        {
          "text": "Bipolar disorder",
          "url": "https://wikem.org/wiki/Bipolar_disorder"
        },
        {
          "text": "Borderline personality disorder",
          "url": "https://wikem.org/wiki/Borderline_personality_disorder"
        },
        {
          "text": "Antipsychotics",
          "url": "https://wikem.org/wiki/Antipsychotics"
        },
        {
          "text": "Antipsychotic toxicity",
          "url": "https://wikem.org/wiki/Antipsychotic_toxicity"
        }
      ]
    }
  }
}